3 New Strong Buy Ratings from Top-Rated Analysts: 09/26/2025

Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

• Why Worthington Steel (WS) is gaining momentum from acquisition potential
• Neurocrine Biosciences (NBIX): A rare biopharma with strong financials 
• With a fantastic earnings guidance upgrade, Tutor Perini (TPC) appears poised for great things

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. Worthington Steel (NYSE: WS) 

Worthington Steel is a newly independent steel processor with deep roots in the industry, spun off from Worthington Industries in 2023 to sharpen its focus on flat-rolled steel solutions. With an emphasis on advanced high-strength and coated steels and a push into lighter and more sustainable materials, WS is poised to benefit from industry trends.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $33.74 — get current quote > 

Max 1-year forecast: $36.00 

Why we’re watching:

• Worthington Steel is quite low-profile — the stock has 1 Strong Buy rating. See the ratings  
• That Strong Buy rating was recently reiterated by KeyBanc’s Matthew Gillmor (a top 9% rated analyst), who also raised his price target from $34 to $36.  
• Factors favoring Worthington Steel's momentum over the next 6 to 12 months, according to Gillmor, include FY 2026 to 2027 estimate revisions, improved auto customer sentiment, and the potential for the company to make larger accretive acquisitions.
• WS is currently the 2nd highest-rated stock in the Steel industry, which has an Industry Rating of B.
• Worthington Steel shares rank in the 91st percentile of the equities that we track, giving them a Zen Rating of B.
• Our Artificial Intelligence Component Grade rating uses a neural network trained on two decades of market data to identify likely outperformers. In this category, WS ranks in the 84th percentile of stocks.
• Worthington Steel also ranks in the 84th percentile of equities with regard to Sentiment.
• Another vote in the stock’s favor is its valuation. WS is currently trading at a price-to-earnings (P/E) ratio of 15.02x, and a price-to-earnings growth (PEG) ratio of 0.99x, so it ranks in the top 12% in terms of Value.
• Lastly, we have Safety — the Component Grade rating that assesses stock price stability, revenue inflow consistency, and earnings predictability. Here, Worthington Steel ranks in the top 10%. (See all 7 Zen Component Grades here >)

2. Neurocrine Biosciences (NASDAQ: NBIX) 

Neurocrine Biosciences is a neuroscience-focused biopharma business that maintains a growing drug pipeline targeting movement disorders, epilepsy, depression, and rare pediatric diseases. The company recently delivered a double beat, and Wall Street’s expectations are rather high — however, NBIX is still trading at a very attractive valuation.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $145.23 — get current quote > 

Max 1-year forecast: $185.00 

Why we’re watching:

• NBIX is tracked by 15 Wall Street equity researchers — their coverage is split between 8 Strong Buy ratings, 5 Buy ratings, and 2 Hold ratings. See the ratings
• In addition, the average 12-month price forecast for Neurocrine Biosciences shares is currently pegged at $160.53, and implies a healthy 10.54% upside. 
• Morgan Stanley’s Jeffrey Hung (a top 11% rated analyst) recently maintained a Strong Buy rating on the stock, and increased his price target from $158 to $163. 
• NBIX is the 9th highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B.
• Neurocrine Biosciences ranks in the top 4% of the stocks that we track, giving it a Zen Rating of A.
• Value is one of NBIX’s strong suits — the stock ranks in the top 8% of equities in this category.
• In terms of its Artificial Intelligence Component Grade rating, Neurocrine Biosciences shares rank in the top 7%.
• Thanks to the company’s robust balance sheet, NBIX currently ranks in the 96th percentile when it comes to Financials. (See all 7 Zen Component Grades here >)

A note from our sponsors...

3. Tutor Perini (NYSE: TPC)

TPC found a place in our exclusive Zen Investor portfolio earlier this month. It’s the highest-rated stock in its industry — it’s also one of the highest-rated stocks overall. A recent earnings beat has put the stock in the limelight — and once you see how earnings estimates have changed, you’ll likely want to scoop up some shares while they’re still relatively cheap.

 Zen Rating:  A (Strong Buy) — see full analysis >  

Recent Price: $64.78 — get current quote > 

Max 1-year forecast: $75.00

Why we’re watching:

• TPC is our Stock of the Week. Our Editor-in-Chief, Steve Reitmeister, explained what makes Tutor Perini such an attractive pick in a Monday article. We’ll summarize some of the key points below.
• At present, Tutor Perini has a Zen Rating of A, and is rated 3rd overall out of the roughly 4,600 stocks that we track.
• TPC is also the highest-rated stock in the Engineering & Construction industry, which has an Industry Rating of A.
• The stock blew everyone’s mind this earnings season. While the company did provide a modest 12% earnings beat, guidance was the star of the show — earnings estimates for this year nearly doubled from $1.81 to $3.34, which has also led to an increase in earnings prospects for 2026, 2027, and beyond.
• TPC ranks in the top 26% of stocks when it comes to Value, and the top 17% in terms of Artificial Intelligence.
• However, Momentum and Growth are Tutor Perini’s strongest suits — in these categories, the stock ranks in the 96th and 99th percentile, respectively. (See all 7 Zen Component Grades here >)

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.